CEO to review dronabinol, a Phase 3-ready medicine for the treatment of obstructive sleep apnea, and…
Continue ReadingTag: obstructive-sleep-apnea
RespireRx Pharmaceuticals Inc. to Present at 9th Annual Biotech Showcase(TM) 2017
CEO to Review Completed Phase 2B Dronabinol Clinical Trial for the Treatment of Obstructive Sleep Apnea…
Continue ReadingRespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE Study Conducted by the University of Illinois Dronabinol Reduces Symptoms of Obstructive Sleep Apnea
GLEN ROCK, NJ -- (Marketwired) -- 12/23/16 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the…
Continue Reading